Genmab A/S · NASDAQ
Sign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about GMAB?
Zacks Investment Research
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating.
Headlines link to the publisher. Not investment advice.
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Sign in to post on $GMAB
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
